Tagomics described a new cell-free DNA blood-test approach for multi-organ drug safety monitoring using its LiquiPath platform, built around tagging and enriching unmethylated genomic regions. The concept positions the assay as a way to track toxicity signals across organs rather than relying solely on traditional imaging or localized biomarkers. In a manufacturing-adjacent clinical execution theme, chilled platelets were reported as extending effective storage duration—potentially up to 21 days—while staying safe in an adaptive trial context. If confirmed broadly, that could reshape transfusion logistics by increasing availability for bleeding patients. Together, the updates point to a practical shift: measurement tools and operational supplies are being engineered to reduce latency between toxicity risk and clinical action.